BioCentury
ARTICLE | Company News

TransTech, Calithera Biosciences deal

March 16, 2015 7:00 AM UTC

TransTech granted cancer company Calithera exclusive, worldwide rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech will receive $600,000 up front and is eligible to receive up to $30.5 million in development and regulatory milestones and up to $77 million in sales milestones, plus mid-single-digit royalties for the first product. ...